Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer.
BACKGROUND
E-cadherin is an epithelial cell adhesion molecule, and decreased E-cadherin expression in human prostate cancer is associated with tumor grade and advanced clinical stage. A -160 C-->A polymorphism in the promoter region of E-cadherin has been shown to decrease gene transcription. This allelic variation may be a potential genetic marker that can help identify those individuals at higher risk for invasive/metastatic disease.


METHODS
We studied the effect of E-cadherin gene polymorphism on prostate cancer susceptibility in a case control study of 219 prostate cancer patients and 219 male controls, to determine whether this polymorphism is a biomarker for the risk and how aggressive the disease is.


RESULTS
The genotype frequencies in the prostate cancer group were C/C: 0.607, C/A: 0.352, A/A: 0.041, and in the control group C/C: 0.671, C/A: 0.301, A/A: 0.027. A significant difference between the two groups was not found (p = 0.34), and the adjusted OR for A/A genotype was not statistically significant (OR = 1.66, 95% CI 0.58-4.78). Subdividing prostate cancer according to tumor differentiation and stage, we found no association between E-cadherin polymorphism and poor differentiation and invasiveness of prostate cancer.


CONCLUSIONS
These data do not support an association between the E-cadherin genotype and the occurrence or progression of prostate cancer in Japanese populations.
Tsukino
Hiromasa
H
Department of Public Health, Miyazaki Medical College, University of Miyazaki, Miyazaki, Japan.
Kuroda
Yoshiki
Y
Imai
Hirohisa
H
Nakao
Hiroyuki
H
Qiu
Delai
D
Komiya
Yasuhiro
Y
Inatomi
Hisato
H
Hamasaki
Takashi
T
Kohshi
Kiyotaka
K
Osada
Yukio
Y
Katoh
Takahiko
T
D000368:Aged; D015820:Cadherins / Q000235:genetics*; D016022:Case-Control Studies; D018450:Disease Progression; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics*; D012307:Risk Factors
D015820:Cadherins